Liver injury in non-severe COVID-19 with various pandemic phases: a real-world study

Winyupakorn et al., Research Square, doi:10.21203/rs.3.rs-3484296/v1

Oct 2023

Source PDF All Studies Meta AnalysisMeta

Prospective study of 300 patients with mild to moderate COVID-19 in Thailand, showing the highest risk of liver injury with molnupiravir treatment, OR 3.4 (p = 0.06).

Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-14.

Important missing comments or errors? Let us know.

liver injury, 241.0% higher, OR 3.41, p = 0.06, treatment 22, control 278, adjusted per study, multivariable, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

2. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

3. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

4. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.hawaii.edu.

5. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

6. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

7. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

8. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

9. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

10. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.asianmedjam.com.

11. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

12. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

13. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

14. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.twitter.com/LongDesertTrain/status/1597353291868155906.

Winyupakorn et al., 31 Oct 2023, prospective, Thailand, preprint, 4 authors, study period September 2021 - October 2022. Contact: supatsri@nmu.ac.th.

This Paper Molnupiravir All

Liver injury in non-severe COVID-19 with various pandemic phases: a real-world study

Jirayuth Winyupakorn, Chunlanee Sangketchon, Watcharaporn Devakul Na Ayutthaya, Supatsri Sethasine

doi:10.21203/rs.3.rs-3484296/v1

The using of a variety of anti-COVID-19 medicines connected to the degree of liver impairment in the short term was intriguing. To evaluate the dynamic course of liver injury in patients with mild to moderate COVID-19 within 10 days of admission. This was a prospective cohort study of 300 patients who were newly proven mild to moderate COVID-19 between September 2021 and October 2022. There were 188 patients in hospitel/ eld hospital (n = 188) and cohort wards (n = 112). One hundred and fteen patients (38.3%) suffered from liver injury (LI). The majority of Group LI participants (n = 104) received medication to treat the COVID-19 infection, including favipiravir (45%), remdesivir (17.4%), molnupiravir (11.3%), Andrographis paniculata (ADG) (8.7%), and favipiravir in combination with ivermectin (7.7%). When compared to no LI, molnupiravir medication was linked with the largest proportion of transaminase < 2 and 2-5 times the ULN [11.3% vs. 4.9%, p = 0.038; 15.2% vs. 4.9%, p = 0.013]. After 10 days, the majority of patients exhibited a transaminase decline. A less-than-critical level of liver damage was reported in mild to moderate COVID-19 that allows clinicians to administer a variety of standard medications during short periods of hospital stay.

We emphasized the real-world dynamics of LI in mild to moderate COVID-19, the less-than-critical state of liver impairment that enables physicians to give a variety of common drugs over the course of the entire hospitalization period. Declarations Data availability The data used in this work are available upon reasonable request from the corresponding author.

References

Asselah, Durantel, Pasmant, Lau, Schinazi, COVID-19: Discovery, diagnostics and drug development, J Hepatol

Cai, Huang, Yu, Zhu, Xia et al., COVID-19: Abnormal liver function tests, J Hepatol

Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet

Fan, Chen, Li, Cheng, Yang et al., Clinical Features of COVID-19-Related Liver Functional Abnormality, Clin Gastroenterol Hepatol

Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med

Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet

Hundt, Deng, Ciarleglio, Nathanson, Lim, Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U, S. Hospital Network. Hepatology

Ji, Qin, Xu, Zhang, Cheng et al., Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study, J Hepatol

Kaewdech, Nawalerspanya, Assawasuwannakit, Chamroonkul, Jandee et al., The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study, Sci Rep

Kaneko, Kurosaki, Nagata, Taki, Ueda et al., Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity, PLoS One

Kulkarni, Kumar, Tevethia, Premkumar, Arab et al., Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19, Aliment Pharmacol Ther

Li, Moore, Vasilieva, Sui, Wong et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature

Ortiz, Lenhart, Becker, Schwambach, Tovo et al., Drug-induced liver injury and COVID-19: A review for clinical practice, World J Hepatol

Phipps, Barraza, Lasota, Sobieszczyk, Pereira et al., Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U, Hepatology

Pontolillo, Ucciferri, Borrelli, Nicola, Vecchiet et al., Molnupiravir as an Early Treatment for COVID-19: A Real Life Study, Pathogens

Singh, Khan, Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study, Gastroenterology

Sodei An, Seyedalhosseini, Kian, Eftekhari, Najari et al., Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review, Front Med

Songvut, Suriyo, Panomvana, Rangkadilok, Satayavivad, A comprehensive review on disposition kinetics and dosage of oral administration of Andrographis paniculata, an alternative herbal medicine, in co-treatment of coronavirus disease, Front Pharmacol

Vespa, Pugliese, Piovani, Capogreco, Danese et al., Liver tests abnormalities in COVID-19: trick or treat?, J Hepatol

Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, Jama

Wijarnpreecha, Ungprasert, Panjawatanan, Harnois, Zaver et al., COVID-19 and liver injury: a meta-analysis, Eur J Gastroenterol Hepatol

Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature

Yu, Du, Yan, Guo, He et al., Liver injury in COVID-19: clinical features and treatment management, Virol J

Zhang, Shi, Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol Hepatol

{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T07:04:38Z', 'timestamp': 1698822278273}, 'posted': {'date-parts': [[2023, 10, 31]]}, 'group-title': 'In Review', 'reference-count': 24, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2023, 10, 31]], 'date-time': '2023-10-31T00:00:00Z', 'timestamp': 1698710400000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2023, 10, 24]]}, 'abstract': 'Abstract\n' ' The using of a variety of anti-COVID-19 medicines connected to the degree of ' 'liver impairment in the short term was intriguing. To evaluate the dynamic course of liver ' 'injury in patients with mild to moderate COVID-19 within 10 days of admission. This was a ' 'prospective cohort study of 300 patients who were newly proven mild to moderate COVID-19 ' 'between September 2021 and October 2022. There were 188 patients in hospitel/field hospital ' '(n = 188) and cohort wards (n = 112). One hundred and fifteen patients (38.3%) suffered from ' 'liver injury (LI). The majority of Group LI participants (n = 104) received medication to ' 'treat the COVID-19 infection, including favipiravir (45%), remdesivir (17.4%), molnupiravir ' '(11.3%), Andrographis paniculata (ADG) (8.7%), and favipiravir in combination with ivermectin ' '(7.7%). When compared to no LI, molnupiravir medication was linked with the largest ' 'proportion of transaminase < 2 and 2–5 times the ULN [11.3% vs. 4.9%, p = 0.038; 15.2% vs. ' '4.9%, p = 0.013]. After 10 days, the majority of patients exhibited a transaminase decline. A ' 'less-than-critical level of liver damage was reported in mild to moderate COVID-19 that ' 'allows clinicians to administer a variety of standard medications during short periods of ' 'hospital stay.', 'DOI': '10.21203/rs.3.rs-3484296/v1', 'type': 'posted-content', 'created': { 'date-parts': [[2023, 10, 31]], 'date-time': '2023-10-31T20:51:28Z', 'timestamp': 1698785488000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Liver injury in non-severe COVID-19 with various pandemic phases: a real-world study', 'prefix': '10.21203', 'author': [ { 'given': 'Jirayuth', 'family': 'Winyupakorn', 'sequence': 'first', 'affiliation': [{'name': 'Vajira Hospital, Navamindradhiraj University'}]}, { 'given': 'Chunlanee', 'family': 'Sangketchon', 'sequence': 'additional', 'affiliation': [{'name': 'Vajira Hospital, Navamindradhiraj University'}]}, { 'given': 'Watcharaporn Devakul Na', 'family': 'Ayutthaya', 'sequence': 'additional', 'affiliation': [{'name': 'Vajira Hospital, Navamindradhiraj University'}]}, { 'given': 'Supatsri', 'family': 'Sethasine', 'sequence': 'additional', 'affiliation': [{'name': 'Vajira Hospital, Navamindradhiraj University'}]}], 'member': '8761', 'reference': [ { 'issue': '1', 'key': 'ref1', 'doi-asserted-by': 'crossref', 'first-page': '168', 'DOI': '10.1016/j.jhep.2020.09.031', 'article-title': 'COVID-19: Discovery, diagnostics and drug development', 'volume': '74', 'author': 'Asselah T', 'year': '2021', 'unstructured': 'Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: ' 'Discovery, diagnostics and drug development. J Hepatol. ' '2021;74(1):168–84.', 'journal-title': 'J Hepatol'}, { 'issue': '6965', 'key': 'ref2', 'doi-asserted-by': 'crossref', 'first-page': '450', 'DOI': '10.1038/nature02145', 'article-title': 'Angiotensin-converting enzyme 2 is a functional receptor for the SARS ' 'coronavirus', 'volume': '426', 'author': 'Li W', 'year': '2003', 'unstructured': 'Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. ' 'Angiotensin-converting enzyme 2 is a functional receptor for the SARS ' 'coronavirus. Nature. 2003;426(6965):450–4.', 'journal-title': 'Nature'}, { 'issue': '1', 'key': 'ref3', 'doi-asserted-by': 'crossref', 'first-page': '121', 'DOI': '10.1186/s12985-021-01593-1', 'article-title': 'Liver injury in COVID-19: clinical features and treatment management', 'volume': '18', 'author': 'Yu D', 'year': '2021', 'unstructured': 'Yu D, Du Q, Yan S, Guo XG, He Y, Zhu G, et al. Liver injury in COVID-19: ' 'clinical features and treatment management. Virol J. 2021;18(1):121.', 'journal-title': 'Virol J'}, { 'issue': '10223', 'key': 'ref4', 'doi-asserted-by': 'crossref', 'first-page': '507', 'DOI': '10.1016/S0140-6736(20)30211-7', 'article-title': 'Epidemiological and clinical characteristics of 99 cases of 2019 novel ' 'coronavirus pneumonia in Wuhan, China: a descriptive study', 'volume': '395', 'author': 'Chen N', 'year': '2020', 'unstructured': 'Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and ' 'clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia ' 'in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.', 'journal-title': 'Lancet'}, { 'issue': '10223', 'key': 'ref5', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang C', 'year': '2020', 'unstructured': 'Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of ' 'patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. ' '2020;395(10223):497–506.', 'journal-title': 'Lancet'}, { 'issue': '11', 'key': 'ref6', 'doi-asserted-by': 'crossref', 'first-page': '1061', 'DOI': '10.1001/jama.2020.1585', 'article-title': 'Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel ' 'Coronavirus-Infected Pneumonia in Wuhan, China', 'volume': '323', 'author': 'Wang D', 'year': '2020', 'unstructured': 'Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical ' 'Characteristics of 138 Hospitalized Patients With 2019 Novel ' 'Coronavirus-Infected Pneumonia in Wuhan, China. Jama. ' '2020;323(11):1061–9.', 'journal-title': 'Jama'}, { 'issue': '18', 'key': 'ref7', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical Characteristics of Coronavirus Disease 2019 in China', 'volume': '382', 'author': 'Guan WJ', 'year': '2020', 'unstructured': 'Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical ' 'Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. ' '2020;382(18):1708–20.', 'journal-title': 'N Engl J Med'}, { 'issue': '3', 'key': 'ref8', 'doi-asserted-by': 'crossref', 'first-page': '566', 'DOI': '10.1016/j.jhep.2020.04.006', 'article-title': 'COVID-19: Abnormal liver function tests', 'volume': '73', 'author': 'Cai Q', 'year': '2020', 'unstructured': 'Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal ' 'liver function tests. J Hepatol. 2020;73(3):566–74.', 'journal-title': 'J Hepatol'}, { 'issue': '11', 'key': 'ref9', 'doi-asserted-by': 'crossref', 'first-page': 'e0241663', 'DOI': '10.1371/journal.pone.0241663', 'article-title': 'Liver injury with COVID-19 based on gastrointestinal symptoms and ' 'pneumonia severity', 'volume': '15', 'author': 'Kaneko S', 'year': '2020', 'unstructured': 'Kaneko S, Kurosaki M, Nagata K, Taki R, Ueda K, Hanada S, et al. Liver ' 'injury with COVID-19 based on gastrointestinal symptoms and pneumonia ' 'severity. PLoS One. 2020;15(11):e0241663.', 'journal-title': 'PLoS One'}, { 'issue': '4', 'key': 'ref10', 'doi-asserted-by': 'crossref', 'first-page': '584', 'DOI': '10.1111/apt.15916', 'article-title': 'Systematic review with meta-analysis: liver manifestations and outcomes ' 'in COVID-19', 'volume': '52', 'author': 'Kulkarni AV', 'year': '2020', 'unstructured': 'Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et ' 'al. Systematic review with meta-analysis: liver manifestations and ' 'outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52(4):584–99.', 'journal-title': 'Aliment Pharmacol Ther'}, { 'issue': '3', 'key': 'ref11', 'doi-asserted-by': 'crossref', 'first-page': '807', 'DOI': '10.1002/hep.31404', 'article-title': 'Acute Liver Injury in COVID-19: Prevalence and Association with ' 'Clinical Outcomes in a Large U.S. Cohort', 'volume': '72', 'author': 'Phipps MM', 'year': '2020', 'unstructured': 'Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, ' 'et al. Acute Liver Injury in COVID-19: Prevalence and Association with ' 'Clinical Outcomes in a Large U.S. Cohort. Hepatology. 2020;72(3):807–17.', 'journal-title': 'Hepatology'}, { 'issue': '7', 'key': 'ref12', 'doi-asserted-by': 'crossref', 'first-page': '1561', 'DOI': '10.1016/j.cgh.2020.04.002', 'article-title': 'Clinical Features of COVID-19-Related Liver Functional Abnormality', 'volume': '18', 'author': 'Fan Z', 'year': '2020', 'unstructured': 'Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical Features ' 'of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol ' 'Hepatol. 2020;18(7):1561–6.', 'journal-title': 'Clin Gastroenterol Hepatol'}, { 'issue': '2', 'key': 'ref13', 'doi-asserted-by': 'crossref', 'first-page': '451', 'DOI': '10.1016/j.jhep.2020.03.044', 'article-title': 'Non-alcoholic fatty liver diseases in patients with COVID-19: A ' 'retrospective study', 'volume': '73', 'author': 'Ji D', 'year': '2020', 'unstructured': 'Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty ' 'liver diseases in patients with COVID-19: A retrospective study. J ' 'Hepatol. 2020;73(2):451–3.', 'journal-title': 'J Hepatol'}, { 'issue': '5', 'key': 'ref14', 'doi-asserted-by': 'crossref', 'first-page': '1275', 'DOI': '10.1016/j.jhep.2020.05.033', 'article-title': 'Liver tests abnormalities in COVID-19: trick or treat?', 'volume': '73', 'author': 'Vespa E', 'year': '2020', 'unstructured': 'Vespa E, Pugliese N, Piovani D, Capogreco A, Danese S, Aghemo A. Liver ' 'tests abnormalities in COVID-19: trick or treat? J Hepatol. ' '2020;73(5):1275–6.', 'journal-title': 'J Hepatol'}, { 'issue': '4', 'key': 'ref15', 'doi-asserted-by': 'crossref', 'first-page': '1169', 'DOI': '10.1002/hep.31487', 'article-title': 'Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort ' 'Study of 1,827 Patients in a Major U.S. Hospital Network', 'volume': '72', 'author': 'Hundt MA', 'year': '2020', 'unstructured': 'Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver ' 'Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 ' 'Patients in a Major U.S. Hospital Network. Hepatology. ' '2020;72(4):1169–76.', 'journal-title': 'Hepatology'}, { 'issue': '1', 'key': 'ref16', 'doi-asserted-by': 'crossref', 'first-page': '18213', 'DOI': '10.1038/s41598-022-23189-7', 'article-title': 'The use of Andrographis paniculata and its effects on liver ' 'biochemistry of patients with gastrointestinal problems in Thailand ' 'during the COVID-19 pandemic: a cross sectional study', 'volume': '12', 'author': 'Kaewdech A', 'year': '2022', 'unstructured': 'Kaewdech A, Nawalerspanya S, Assawasuwannakit S, Chamroonkul N, Jandee ' 'S, Sripongpun P. The use of Andrographis paniculata and its effects on ' 'liver biochemistry of patients with gastrointestinal problems in ' 'Thailand during the COVID-19 pandemic: a cross sectional study. Sci Rep. ' '2022;12(1):18213.', 'journal-title': 'Sci Rep'}, { 'key': 'ref17', 'doi-asserted-by': 'crossref', 'first-page': '952660', 'DOI': '10.3389/fphar.2022.952660', 'article-title': 'A comprehensive review on disposition kinetics and dosage of oral ' 'administration of Andrographis paniculata, an alternative herbal ' 'medicine, in co-treatment of coronavirus disease', 'volume': '13', 'author': 'Songvut P', 'year': '2022', 'unstructured': 'Songvut P, Suriyo T, Panomvana D, Rangkadilok N, Satayavivad J. A ' 'comprehensive review on disposition kinetics and dosage of oral ' 'administration of Andrographis paniculata, an alternative herbal ' 'medicine, in co-treatment of coronavirus disease. Front Pharmacol. ' '2022;13:952660.', 'journal-title': 'Front Pharmacol'}, { 'issue': '9', 'key': 'ref18', 'doi-asserted-by': 'crossref', 'first-page': '1143', 'DOI': '10.4254/wjh.v13.i9.1143', 'article-title': 'Drug-induced liver injury and COVID-19: A review for clinical practice', 'volume': '13', 'author': 'Ortiz GX', 'year': '2021', 'unstructured': 'Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. ' 'Drug-induced liver injury and COVID-19: A review for clinical practice. ' 'World J Hepatol. 2021;13(9):1143–53.', 'journal-title': 'World J Hepatol'}, { 'key': 'ref19', 'doi-asserted-by': 'crossref', 'first-page': '731436', 'DOI': '10.3389/fmed.2021.731436', 'article-title': 'Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review', 'volume': '8', 'author': 'Sodeifian F', 'year': '2021', 'unstructured': 'Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, ' 'Mirsaeidi M, et al. Drug-Induced Liver Injury in COVID-19 Patients: A ' 'Systematic Review. Front Med (Lausanne). 2021;8:731436.', 'journal-title': 'Front Med (Lausanne)'}, { 'issue': '10', 'key': 'ref20', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/pathogens11101121', 'article-title': 'Molnupiravir as an Early Treatment for COVID-19: A Real Life Study', 'volume': '11', 'author': 'Pontolillo M', 'year': '2022', 'unstructured': 'Pontolillo M, Ucciferri C, Borrelli P, Di Nicola M, Vecchiet J, Falasca ' 'K. Molnupiravir as an Early Treatment for COVID-19: A Real Life Study. ' 'Pathogens. 2022;11(10).', 'journal-title': 'Pathogens'}, { 'issue': '7', 'key': 'ref21', 'doi-asserted-by': 'crossref', 'first-page': '990', 'DOI': '10.1097/MEG.0000000000001817', 'article-title': 'COVID-19 and liver injury: a meta-analysis', 'volume': '33', 'author': 'Wijarnpreecha K', 'year': '2021', 'unstructured': 'Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, ' 'Ahmed A, et al. COVID-19 and liver injury: a meta-analysis. Eur J ' 'Gastroenterol Hepatol. 2021;33(7):990–5.', 'journal-title': 'Eur J Gastroenterol Hepatol'}, { 'issue': '5', 'key': 'ref22', 'doi-asserted-by': 'crossref', 'first-page': '428', 'DOI': '10.1016/S2468-1253(20)30057-1', 'article-title': 'Liver injury in COVID-19: management and challenges', 'volume': '5', 'author': 'Zhang C', 'year': '2020', 'unstructured': 'Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and ' 'challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–30.', 'journal-title': 'Lancet Gastroenterol Hepatol'}, { 'issue': '2', 'key': 'ref23', 'doi-asserted-by': 'crossref', 'first-page': '768', 'DOI': '10.1053/j.gastro.2020.04.064', 'article-title': 'Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among ' 'Patients With Preexisting Liver Disease in the United States: A ' 'Multicenter Research Network Study', 'volume': '159', 'author': 'Singh S', 'year': '2020', 'unstructured': 'Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus ' 'Disease 2019 Among Patients With Preexisting Liver Disease in the United ' 'States: A Multicenter Research Network Study. Gastroenterology. ' '2020;159(2):768 – 71.e3.', 'journal-title': 'Gastroenterology'}, { 'issue': '7821', 'key': 'ref24', 'doi-asserted-by': 'crossref', 'first-page': '430', 'DOI': '10.1038/s41586-020-2521-4', 'article-title': 'Factors associated with COVID-19-related death using OpenSAFELY', 'volume': '584', 'author': 'Williamson EJ', 'year': '2020', 'unstructured': 'Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et ' 'al. Factors associated with COVID-19-related death using OpenSAFELY. ' 'Nature. 2020;584(7821):430–6.', 'journal-title': 'Nature'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-3484296/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-3484296/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 10, 31]], 'date-time': '2023-10-31T20:51:52Z', 'timestamp': 1698785512000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-3484296/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 10, 31]]}, 'references-count': 24, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-3484296/v1', 'relation': {}, 'published': {'date-parts': [[2023, 10, 31]]}, 'subtype': 'preprint'}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0